300 related articles for article (PubMed ID: 35323080)
1. Targeting triglycerides to lower residual cardiovascular risk.
Bubb KJ; Nelson AJ; Nicholls SJ
Expert Rev Cardiovasc Ther; 2022 Mar; 20(3):185-191. PubMed ID: 35323080
[TBL] [Abstract][Full Text] [Related]
2. The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk.
Sandesara PB; Virani SS; Fazio S; Shapiro MD
Endocr Rev; 2019 Apr; 40(2):537-557. PubMed ID: 30312399
[TBL] [Abstract][Full Text] [Related]
3. Triglyceride-Rich Lipoproteins and Their Remnants as Silent Promoters of Atherosclerotic Cardiovascular Disease and Other Metabolic Disorders: A Review.
Sascău R; Clement A; Radu R; Prisacariu C; Stătescu C
Nutrients; 2021 May; 13(6):. PubMed ID: 34067469
[TBL] [Abstract][Full Text] [Related]
4. Triglyceride-rich lipoproteins and cardiovascular diseases.
Xu D; Xie L; Cheng C; Xue F; Sun C
Front Endocrinol (Lausanne); 2024; 15():1409653. PubMed ID: 38883601
[TBL] [Abstract][Full Text] [Related]
5. TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS.
Handelsman Y; Shapiro MD
Endocr Pract; 2017 Jan; 23(1):100-112. PubMed ID: 27819772
[TBL] [Abstract][Full Text] [Related]
6. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease risk: current status and treatments.
Reyes-Soffer G
Curr Opin Endocrinol Diabetes Obes; 2021 Apr; 28(2):85-89. PubMed ID: 33481422
[TBL] [Abstract][Full Text] [Related]
7. Triglycerides and risk of atherosclerotic cardiovascular disease: An update.
Farnier M; Zeller M; Masson D; Cottin Y
Arch Cardiovasc Dis; 2021 Feb; 114(2):132-139. PubMed ID: 33546998
[TBL] [Abstract][Full Text] [Related]
8. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management.
Chapman MJ; Ginsberg HN; Amarenco P; Andreotti F; Borén J; Catapano AL; Descamps OS; Fisher E; Kovanen PT; Kuivenhoven JA; Lesnik P; Masana L; Nordestgaard BG; Ray KK; Reiner Z; Taskinen MR; Tokgözoglu L; Tybjærg-Hansen A; Watts GF;
Eur Heart J; 2011 Jun; 32(11):1345-61. PubMed ID: 21531743
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in treating hypertriglyceridemia in patients at high risk of cardiovascular disease with apolipoprotein C-III inhibitors.
Spagnuolo CM; Hegele RA
Expert Opin Pharmacother; 2023 Jun; 24(9):1013-1020. PubMed ID: 37114828
[TBL] [Abstract][Full Text] [Related]
10. New Therapies for Lowering Triglyceride-Rich Lipoproteins: JACC Focus Seminar 3/4.
Rosenson RS; Shaik A; Song W
J Am Coll Cardiol; 2021 Nov; 78(18):1817-1830. PubMed ID: 34711341
[TBL] [Abstract][Full Text] [Related]
11. Remnant cholesterol, vascular risk, and prevention of atherosclerosis.
Pintó X; Fanlo M; Esteve V; Millán J;
Clin Investig Arterioscler; 2023; 35(4):206-217. PubMed ID: 36889989
[TBL] [Abstract][Full Text] [Related]
12. Residual Cardiovascular Risk at Low LDL: Remnants, Lipoprotein(a), and Inflammation.
Hoogeveen RC; Ballantyne CM
Clin Chem; 2021 Jan; 67(1):143-153. PubMed ID: 33257928
[TBL] [Abstract][Full Text] [Related]
13. Dyslipidemias and Cardiovascular Prevention: Tailoring Treatment According to Lipid Phenotype.
Sanin V; Pfetsch V; Koenig W
Curr Cardiol Rep; 2017 Jul; 19(7):61. PubMed ID: 28528455
[TBL] [Abstract][Full Text] [Related]
14. Triglyceride-Rich Lipoproteins and Remnant Cholesterol in Cardiovascular Disease.
Heo JH; Jo SH
J Korean Med Sci; 2023 Sep; 38(38):e295. PubMed ID: 37750369
[TBL] [Abstract][Full Text] [Related]
15. Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology.
Nordestgaard BG
Circ Res; 2016 Feb; 118(4):547-63. PubMed ID: 26892957
[TBL] [Abstract][Full Text] [Related]
16. Lipid pharmacotherapy for treatment of atherosclerosis.
Nicholls SJ; Pisaniello AD; Kataoka Y; Puri R
Expert Opin Pharmacother; 2014 Jun; 15(8):1119-25. PubMed ID: 24702590
[TBL] [Abstract][Full Text] [Related]
17. New targets and mechanisms of action for lipid-lowering and anti-inflammatory therapies in atherosclerosis: where does the field stand?
Nicholls SJ; Nelson AJ
Expert Opin Ther Targets; 2024 May; 28(5):375-384. PubMed ID: 38815057
[TBL] [Abstract][Full Text] [Related]
18. Human Angiopoietin-like Protein 3/ANGPTL3 Antibodies: Adding to the Armamentarium in the Management of Dyslipidemia.
Wiggins BS
J Cardiovasc Pharmacol; 2021 Nov; 78(5):e631-e640. PubMed ID: 34738550
[TBL] [Abstract][Full Text] [Related]
19. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society.
Ginsberg HN; Packard CJ; Chapman MJ; Borén J; Aguilar-Salinas CA; Averna M; Ference BA; Gaudet D; Hegele RA; Kersten S; Lewis GF; Lichtenstein AH; Moulin P; Nordestgaard BG; Remaley AT; Staels B; Stroes ESG; Taskinen MR; Tokgözoğlu LS; Tybjaerg-Hansen A; Stock JK; Catapano AL
Eur Heart J; 2021 Dec; 42(47):4791-4806. PubMed ID: 34472586
[TBL] [Abstract][Full Text] [Related]
20. From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk.
Shapiro MD; Fazio S
Circ Res; 2016 Feb; 118(4):732-49. PubMed ID: 26892970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
